Lynch Syndrome Vaccine Study identifier:
NCT05419011 (

Testing A Combination Of Vaccines For Cancer Prevention In Lynch Syndrome

Study Contact Information:

For more information, please contact [email protected]

About the Study

Lynch Syndrome (LS) increases the risk of colon cancer and other cancers, including cancer of the uterus, ovaries, small bowel, stomach, pancreas, urinary tract, skin, and brain.

This study is being done to assess the safety and effectiveness of a series of vaccines (Tri-Ad5), together with another drug (N-803) that magnifies the body’s response to vaccines, to see if there is an effect on the risk of developing colon and other cancers in LS patients.

For more Information, visit

What the Study Involves

If you consent and are eligible to join this trial, you will attend a total of 8 study appointments. During these visits you will receive a series of injections (3-4 injections four times over a one-year period) and undergo yearly colonoscopies as part of routine care. You can also expect physical exams, blood draws, review of your medical history, and completion of questionnaires and a vaccine report card to report any injection side effects.

Study Locations







This Study is Open To:

People 18 years or older who:

This Study is Not Open To:

People who do not meet the eligibility criteria defined above and those who:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.